ClinicalTrials.gg
CompletedNCT00317226Updated Feb 20, 2018Results posted

Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

A Phase 3 interventional study of Ferric Carboxymaltose (FCM) in Anemia, sponsored by American Regent, Inc.. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2018-02-20.

Sponsored by American Regent, Inc. (part of Daiichi Sankyo) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
145
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing ferric carboxymaltose in Anemia — 3 open to participants now, 3 under way, none of them phase 3. ferric carboxymaltose · Anemia.

Enrollment
29th of 54
145 · median 156
Started
2005
with 4 others
Phase 3
23 of 54
none open now
Registered
1st of 54
by date
Lead sponsor
11 of 54
American Regent, Inc.

Among the 54 studies testing ferric carboxymaltose in Anemia, this one is the 29th largest by enrollment, is one of 5 that started in 2005, is one of 23 in phase 3, and was the 1st registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

3 of the 54 studies testing ferric carboxymaltose in Anemia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ferric carboxymaltose

ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing ferric carboxymaltose in Anemia, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the long term safety and tolerability of an iron maintenance dosing strategy utilizing VIT45 in the treatment of anemia of non-dialysis dependent chronic kidney disease (NDD-CKD). This study is a long term extension to protocol 1VIT04004 (NCT00317239).

Read the detailed description

The primary objective of this study is to evaluate the long term safety and tolerability of an iron maintenance dosing strategy utilizing VIT45 in the treatment of anemia of non-dialysis dependent chronic kidney disease (NDD-CKD). This study is a long term extension to protocol 1VIT04004.

In this study patients that complete protocol 1VIT 04004 or are discontinued will be offered to participate in this extension study.

03

Conditions studied

  • Anemia

Keywords

  • Anemia
  • CKD
  • Chronic Kidney Disease
  • Iron
  • Maintenance Dose
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who completed or discontinued Protocol 1VIT04004

Exclusion criteria

Exclusion Criteria:

  • Known reaction to VIT-45
  • Anemia not related to CKD
  • Chronic, serious infection
  • Recent IV iron other than study drug in past 12 weeks
  • Recent blood loss within the last 12 weeks
  • Need for surgery or dialysis
  • Female subjects who are pregnant or lactating
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
145 participants (actual)

Study arms

  • Experimental
    Ferric Carboxymaltose (FCM)

    maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit

    Drug: Ferric Carboxymaltose (FCM)

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events

    Time frame: 44 week study duration

07

Results

Posted Jun 10, 2015

Participant flow

Hospitals and medical clinics

Participant flow — Overall Study
MilestoneFerric Carboxymaltose (FCM)
Started127
Completed104
Not completed23

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events
Time frame:
44 week study duration
Reported as:
Number · each event
Incidence of Treatment-emergent Adverse Events
each eventFerric Carboxymaltose (FCM)
Incidence of Treatment-emergent Adverse Events84

Adverse events

Collected over 1 year and 8 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ferric Carboxymaltose (FCM)—23/127 (18.1%)23/127 (18.1%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventFerric Carboxymaltose (FCM)
CellulitisInfections and infestations2/127
Acute myocardial infarctionCardiac disorders1/127
Angina unstableCardiac disorders1/127
Coronary artery diseaseCardiac disorders1/127
Abdominal painGastrointestinal disorders1/127
Gastrointestinal hemorrhageGastrointestinal disorders1/127
Large intestine perforationGastrointestinal disorders1/127
NauseaGastrointestinal disorders1/127
Rectal hemorrhageGastrointestinal disorders1/127
VomitingGastrointestinal disorders1/127
Most frequent other events
Most frequent other events
EventFerric Carboxymaltose (FCM)
Odema peripheralGeneral disorders9/127
Urinary tract infectionInfections and infestations7/127
HypertensionVascular disorders7/127

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ferric Carboxymaltose (FCM)
<=18 years0
Between 18 and 65 years61
>=65 years66
Age, Continuous
Age, Continuous(years)Ferric Carboxymaltose (FCM)
Mean65.6 ± 13.39
Sex: Female, Male
Sex: Female, Male(Participants)Ferric Carboxymaltose (FCM)
Female85
Male42
Region of Enrollment
Region of Enrollment(participants)Ferric Carboxymaltose (FCM)
United States127
08

Study locations

1 site
  • Luitpold Pharmaceuticals Inc.
    Norristown, Pennsylvania 19403, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2005, a primary completion of Mar 2007 and a completion of Sep 2007. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2015, 8 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2006
First posted
Apr 24, 2006
Start
Jun 2005
Primary completionActual
Mar 2007
CompletionActual
Sep 2007
Results first posted
Jun 10, 2015
Last update
Feb 20, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00317226
Responsible party
Sponsor
First posted
Apr 24, 2006
Start date
Jun 2005
Primary completion
Mar 2007
Completion
Sep 2007
Results posted
Jun 10, 2015
Last update
Feb 20, 2018

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ferric carboxymaltose

Start the discussion